Financial Daily from THE HINDU group of publications
Thursday, Nov 11, 2004

Cross Currency

Group Sites

Corporate - Mergers & Acquisitions

Jubilant to sell 10.4% stake to Citigroup, Henderson — To fund acquisition in the US

Ambarish Mukherjee

New Delhi , Nov. 10

JUBILANT Organosys Ltd is selling a part of the company's equity through private placement to the Citigroup and the Henderson group for Rs 225 crore to fund its planned acquisition in the US.

Though Jubilant is yet to finalise its acquisition in the US, informed sources said that a core team within the company is already studying details of a number of US pharmaceutical companies whose business profiles could be a "strategic fit" with Jubilant's overseas ambitions.

Jubilant Organosys announced on Wednesday that two global investors - CVC International (a unit of Citigroup Global Investments) and HPC Mauritius Ltd (a unit of Henderson Investment Management) - would be picking up around 10.4 per cent equity in the company through private placement on a preferential allotment basis.

While Citigroup would be chipping in Rs 135 crore for 16.36 lakh equity shares, the Henderson unit would be investing Rs 90 crore for 10.09 lakh equity shares of the company. Jubilant would be making the preferential allotment of equity shares (with a face value of Rs 5 each) to the foreign investors at a price of Rs 825 per share and a lock-in period of one year.

Informed sources told Business Line that the company had been looking at the US market for acquisitions for more than six months now and was awaiting some fund infusion before moving ahead with its plans.

"Now that the company would have the funds, it is likely to move fast on the acquisition front also, because the teething problems of its earlier European acquisitions are also getting over," sources said.

Commenting on the private placement of equities with Citigroup and Henderson, the Chairman and Managing Director of the company, Mr Shyam S. Bhartia, said that the company's "growth outlook remains strong and the raising of further capital will strengthen our financial structure enabling us to rapidly pursue and implement our corporate initiatives. We are delighted to have high quality investors like Citigroup and Henderson as equity holders in the company. The funds raised will be deployed to augment our growth platform, which should resultantly create incremental value for all our shareholders."

More Stories on : Mergers & Acquisitions | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Drug withdrawal may impact generic cos

More products in offing: Biocon
Panacea launches osteoarthritis drug
Biocon launches bio insulin
Lakshadweep gets 9th solar plant from BHEL
Schoeller Tech plant starts operations
`In advertising, get simple, get real'
BPL lenders to move Kerala HC to push through recast package
UB Group looking to bid for SWC liquor biz; Jumbo unmoved
Bunge to merge trading, manufacturing arms
Jubilant to sell 10.4% stake to Citigroup, Henderson — To fund acquisition in the US
Rajasthan Spinning to buy 60% in Jaipur Polyspin
SEBI clears Jindal group co plan to pick SISCOL stake
Phoenix Mecano sets up facility in Pune
Excise exemption for new units in Kutch extended by one year
ITC seeks shareholder nod for change in objects clause of MoA
Gati board clears 1:2 rights offer
Tata Steel targets 15 mt output by 2015
DVC to relook at hydel projects in Bengal, Jharkhand — Appoints CWC to study potential
Software company promoters held for duping depositors in Vizag

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line